Savara Inc.

Savara Inc.

SVRA·NASDAQ

$5.25

+1.9%
HealthcareBiotechnology

Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.

At a Glance

Live Snapshot
Market Cap$1.08B
EPS-0.5300
P/E Ratio-9.91
Earnings Date08/06/2026

svra

Research Development Expenses

Last Annual Value

81.40M

3-Year CAGR

43%

5-Year CAGR

18%

10-Year CAGR

11%

Savara Inc.

Savara Inc. Competitors Analysis of research-development-expenses

SVRA · NASDAQ
Companyresearch-development-expenses
CAGR 3Y
CAGR 5Y
CAGR 10Y
SVRA logo
Savara Inc.
NASDAQ:SVRA
81.40M
22.5%22.9%25.8% 
251.07M
29.6%24.3%28.5%
73.72M
-16.2%-3.0%15.1%
RZLT logo
Rezolute, Inc.
NASDAQ:RZLT
61.53M
12.0%32.6%20.6%
125.10M
59.9%N/AN/A
132.16M
4.7%11.2%N/A
102.93M
18.1%37.9%N/A
221.04M
50.6%50.6%31.4%
PROK logo
ProKidney Corp.
NASDAQ:PROK
114.12M
2.3%19.8%N/A
Savara Inc.

Savara Inc. Fair Value Envelope

SVRA · NASDAQ

Our analysis suggests that SVRA has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $5.25, this represents a potential HIDDEN relative to our calculated worth for Savara Inc..

Intrinsic Value
Current Price: $5.25